Published in final edited form as:

Eur J Clin Microbiol Infect Dis. 2010 August ; 29(8): 927–935. doi:10.1007/s10096-010-0960-9.

Cryptosporidiosis: Environmental, therapeutic, and preventive challenges

Stefan Collinet-Adler, M.D.^{1,2,3} and Honorine D. Ward, M.D.^{1,2}

¹Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA

²Tufts University, Boston, MA

Abstract

Cryptosporidium spp. are responsible for endemic and epidemic disease worldwide. Clinical manifestations may include acute, persistent, or chronic diarrhea, biliary, and pulmonary disease. Disease severity ranges from asymptomatic or mild to severe, intractable diarrhea with wasting depending on immune status, nutrition, and age. Transmission is fecal-oral with both human and animal reservoirs. Disease is often self limited in healthy individuals, but therapy remains a challenge in the immune-compromised. Prevention currently depends on appropriate hygiene and proper water management and treatment.

Keywords

Cryptosporidium; diarrhea; water; therapy; prevention

Introduction

Cryptosporidium spp. are a major cause of concern for potable water supplies and play a significant role in diarrheal illness worldwide. This protozoan parasite of the apicomplexan phylum was first discovered in the gastric mucosa of mice by Tyzzer in 1907 [1], but its medical significance was not recognized until the first biopsy-diagnosed human cases in 1976 [2, 3].

Prevalence

Cryptosporidium spp. infection is prevalent worldwide. Older reports reveal rates varying from 0.26–22% (mean 2.2%) in immunocompetent patients with diarrhea in developed countries versus 1.4–40.9% (mean 6.1%) in developing countries. In HIV-positive patients, rates between 6–70% (mean 14%) were found in developed countries versus 8.7–48% (24%) in developing countries. Up to 7.5% of controls without diarrhea also harbored *Cryptosporidium* spp. [4]. These reports used stool microscopy for detection. However, recent studies suggest that these rates are likely to be higher if PCR is used for detection [5].

³Corresponding author. Tufts Medical Center, Box #41, 800 Washington Street, Boston, Massachusetts, 02111, U.S.A.; Telephone 00 1 617 636 1109; Fax 00 1 617 636 3216; scollinet-adler@tuftsmedicalcenter.org.

Conflicts of interest--SCA and HDW: none.

Seroprevalence rates, which may detect asymptomatic and non-diagnosed cases, are approximately 16.9–54% in the United States, 33–88% in Southern and Eastern Europe, and 64–94.6% in resource poor settings. Seroprevalence increases with age and depends on the quality of water sources [6–13]. However, serology is not a good diagnostic tool since it does not necessarily reflect active infection. Reported non-outbreak *Cryptosporidium* cases in the US increased from 3,411 in 2004 to almost 8,300 in 2007. There were 7 recreational water outbreaks reported in the US in 2004 versus 26 in 2007. This may be due to increased incidence, increased testing, improved surveillance, or a combination of the three [14].

Diagnosis

Oocysts can be identified by stool microscopy with modified acid fast stains, but an experienced operator is necessary to distinguish *Cryptosporidium* spp. from debris, yeast forms and other protozoa. Sensitivity using one sample has been found to be insufficient [15] and therefore several samples should be tested when the diagnosis is strongly suspected [16]. Enzyme linked immunosorbent assays (ELISA) generally have excellent sensitivities and specificities but false positives have been reported [17]. Immunomagnetic separation of oocysts can increase sensitivity in clinical samples [18]. Inhomogeneous distribution of the parasite in biopsy material may result in false negatives [19]. Other detection methods include PCR, immunofluorescence microscopy, colorimetric in situ hybridization, fluorescent in situ hybridization, and real time quantitative PCR but these methods are mainly used for environmental or epidemiological research purposes. Analysis of the small-subunit rRNA locus by PCR RFLP is generally used to determine species. Sub-types can be identified by PCR RFLP or sequencing of polymorphic loci, the most commonly used being the *Cpgp40/15* (also called GP60) locus [20].

Detection of oocysts in environmental samples

Analysis of environmental samples for oocysts generally involves concentration by centrifugation and filtration, purification through immunomagnetic separation, staining using fluorescently labeled monoclonal antibodies and 4',6-diamidino-2-phenylindole (DAPI), and fluorescence and differential interference contrast (DIC) microscopy for visualization [21]. Several methods for assessing viability and infectivity of oocysts in environmental samples exist. One comparison of dye permeability assays with excystation and animal infectivity assays found that permeability patterns could predict infectivity [22]. However, other studies showed that dye permeability and excystation assays over-estimate infectivity [23]. Fluorescent in situ hybridization (FISH) targeting rRNA coupled with fluorescein isothiocyanate (FITC)-conjugated monoclonal antibody allows species specific identification and permits viability assessment [24–26]. However, overestimation of viability and infectivity is a concern [27]. Neonatal mouse infection assays and human ileo-cecal adenocarcinoma-8 (HCT-8) cell culture assays are considered the gold standard for assessing infectivity, but are resource and time intensive. [28]. Additionally, the neonatal mouse model cannot be used to study *C. hominis*.

Life cycle

The life cycle begins with ingestion of viable, infective oocysts by a susceptible host. Excystation of the oocyst results in liberation of four sporozoites that invade and are engulfed by the apical surface of the intestinal epithelium after recognition and attachment to surface receptors. A dense matrix of cytoskeletal elements isolates the host cytoplasm from the parasite, resulting in a supra-cytoplasmic parasitophorous vacuole. Within parasitophorous vacuoles, sporozoites differentiate into trophozoites that undergo asexual merogony resulting in infection of adjacent cells by released merozoites. Alternatively, merozoites may differentiate into type II meronts producing either micro- or macrogametocytes that engage in a sexual cycle. The zygotes thus formed undergo meiosis to produce oocysts with four sporozoites. Thin walled oocysts are implicated in autoinfection, while immediately infectious thick walled oocysts are excreted into the environment to restart the cycle [29, 30]

Transmission

Transmission of *Cryptosporidium* spp. is fecal oral and often linked to contaminated drinking water, but person to person, recreational water, food-borne [31], and zoonotic [32] transmission also occur. Aspiration and hematogenous spread have been proposed to explain respiratory symptoms associated with isolation of *Cryptosporidium* spp. in the airways [33]. Airborne transmission has also been postulated [34]. Mechanical transport of infectious oocysts by flies and other insects has been experimentally proved [35].

Reservoir characteristics and environmental factors influence the epidemiology and transmissibility of *Cryptosporidium* spp. *Cryptosporidium* spp. are immediately infectious when excreted from reservoir species into the environment. However, oocysts are sensitive to inactivation by several adverse environmental conditions before a suitable new host is found.

Animal husbandry involving cattle, and possibly goats and sheep, has been implicated in human outbreaks [36–38]. An epidemic of foot and mouth disease in cattle in 2001 in the UK leading to culling operations and restrictions in animal movement resulted in a significant decrease in human *Cryptosporidium* cases [39]. Young calves have been found to be a greater reservoir for *C. parvum* than older calves and adult cattle [40].

Temperature is a critical parameter in the survival and infectivity of oocysts shed into the environment. Higher temperatures increase metabolic activity, exhausting carbohydrate energy stores, and decrease autonomous survival and infectivity [41]. Oocysts are less infective with age [19] and are very susceptible to desiccation [42].

Exposure to sunlight for 10 hours renders oocysts entirely noninfective in mouse models [43]. Using batch process solar disinfection (SODIS) and vital dye tests, 12 hours of strong sunlight led to a reduction in oocyst viability from 98% to 0.3%. Isolated UV light, particularly UV-B and artificial UV-C, is rapidly germicidal for *Cryptosporidium* spp. [44–46]. *C. parvum* loses infectivity in a mouse model after 150 minutes of exposure to UV light [47]. Despite DNA repair genes, oocysts do not regain infectivity after exposure to UV light

[48]. *C. hominis* is as sensitive to UV light as *C. parvum* [49]. The effect of solar light is not limited to its UV component as exposure of oocysts to UV-shielded autumnal solar radiation reduced mean infectivity by 52% [45].

Vegetation cover can effectively reduce the number of *Cryptosporidium* spp. transferred from stool on land to water. Vegetated buffer zones of 1.1 to 2.1 meters between sources of oocysts and water bodies were found to result in a 3.2 to 8.8 log reduction of oocysts depending on residual dry vegetation matter, land slope, rainfall, and runoff conditions [50].

Incidence of *Cryptosporidium* spp. infections exhibit seasonal variations. Oocyst concentrations in agricultural runoff have been found to be highest at the beginning of storm events and storm seasons [36]. Some investigators, however, have not found any consistent relationship between intensity of rainfall and oocyst contamination of watercourses [51]. In Massachusetts, USA, *Cryptosporidium* spp. incidence peaks approximately 40 days after temperature peaks [52]. A recent meta-analysis revealed a seasonal relationship between cryptosporidiosis, temperature, and the first annual peak in precipitation in moist tropical climates. The meta-analysis of colder temperate climates revealed a slight seasonal peak of cryptosporidiosis in the fall, associated with relatively higher precipitation [53]. Peak human infections in East Africa coincide with the end of the rainy season and an increase in *Cryptosporidium* spp. -contaminated surface waters in Meru, Kenya [54].

Clinical Manifestations

Clinical manifestations vary considerably according to immune status. The infectious dose varies from 9–2066 oocysts depending on strain [55–59] with the infectious dose necessary to infect 50% of subjects (ID₅₀) estimated at 10–83 for *C. hominis* [57] and 132 for *C. parvum* [58]. Subsequent infections in otherwise healthy hosts result in decreased oocyst shedding and clinical severity as well as 20 fold higher ID₅₀s [60, 61]. The pre-patent period, the period between ingestion and excretion of oocysts has been experimentally found to be 5 days on average with a range of 4–9 days using various *C. parvum* isolates [55, 59]. Symptoms may begin before passage of oocysts [55]. In immune competent individuals, symptoms are variable but typically include self-limited watery or mucoid diarrhea. Asymptomatic carriage also occurs. The median duration of symptoms was 9 days (1–51 days) in the 1993 Milwaukee outbreak [62]. In contrast, *Cryptosporidium* spp. is a common cause of persistent (>14 days) diarrhea in malnourished children in the developing world [63, 64]. Stool leukocytes or blood are unusual and should prompt a search for co-infection or an underlying pathology. Possible accompanying symptoms include abdominal cramps, nausea, vomiting, and fever [62, 65, 66]. Asymptomatic oocyst passage has been observed up to two months after resolution of symptoms [15]. Infections after apparent resolution are not infrequent, occurring in up to 40% of cases; however, it is not clear whether these are relapses or reinfections [62, 67]. In immunodeficient individuals, such as HIV/AIDS patients with CD4 counts <50, the course can be chronic, severe, even fulminant leading to wasting and death. Extra-intestinal manifestations are frequently seen in this group. Biliary pathology including sclerosing cholangitis, acalculous cholecystitis, and/or pancreatitis correlates with shortened survival [68]. Respiratory involvement ranging from no symptoms to bilateral infiltrates with dyspnea can occur [69]. The incidence of severe HIV-associated

Cryptosporidium spp. infection has decreased in the developed world with the generalization of effective anti-retroviral therapy [70, 71].

Children in resource poor settings are particularly at risk not only for increased incidence of *Cryptosporidium* spp. infection, but also for increased acute and long-lasting morbidity. Psychomotor developmental stunting may occur following infection, especially in children under 1 year of age, and its effects are still measurable many years after infection [72, 73]. Malnutrition is both a contributing factor to and a result of *Cryptosporidium* spp. infection [74, 75]. In this environment, malnutrition, immune immaturity, and HIV often combine to multiply the impact of *Cryptosporidium* spp. infection. Not surprisingly, cryptosporidiosis has been found to be a major independent risk factor for childhood mortality in the developing world [76].

Species and subtypes

Zoonotic potential and inter-host infectivity of specific species are important in formulating public health measures. Identification at the species level permits preferential tracking of species known to have human infectivity in water sources [77]. *Cryptosporidium hominis* [78] and *C. parvum* are the species most often implicated in human disease. *C. hominis* was initially thought to be infectious only for humans and gnotobiotic piglets [78]; however, more recent studies indicate that this species may also infect other animals [79]. In the US and in many developing countries, *C. hominis* has been shown to be the dominant species involved in human infection. In developing nations, *C. parvum* is predominately anthroponotic, while zoonotic transmission may occur more frequently in developed countries. Other species that less commonly cause zoonotic transmission of *Cryptosporidium* to humans and possibly anthroponotic disease include *C. andersoni* (cattle), *C. canis* (dogs), *C. felis* (cats), *C. meleagridis* (birds), *C. suis* (pigs), and *C. muris* (mice). Cervine (deer), skunk, chipmunk I, horse, and rabbit genotypes may be unusual human pathogens [20].

In urban slums in Brazil, *C. hominis* infections were more common and associated with higher disease burden and greater growth faltering than *C. parvum* infections [80]. *C. hominis* has also been found to be associated with greater severity of diarrhea [81]. Additionally, *C. hominis*, but not *C. parvum* infection, was linked to extra-intestinal sequelae such as arthralgias, ocular pain, recurrent headaches, dizziness, and fatigue [67]. A longitudinal birth cohort study in Peru revealed that first infections with all isolated *Cryptosporidium* spp. were associated with diarrhea, but only *C. hominis* subtype Ib was also associated with nausea, vomiting, and malaise [82]. In contrast, HIV positive patients in India were more likely to have fever when infected with zoonotic species than with *C. hominis* [83]. In HIV patients in Peru, species and subtypes associated with diarrhea included *C. hominis* subtype Id, and *C. felis* or *canis*; however, only *C. parvum* was significantly associated with chronic diarrhea and vomiting. In the same study, *C. meleagridis* infection was not associated with symptoms [84]. Further studies are needed to clarify clinical associations of infection with different species and subtypes.

Immunity

Iterative infection confers immunity in individuals with an intact immune system [60]. The exact mechanisms of protective immunity are not well understood and likely involve innate and adaptive as well as cell-mediated and humoral responses. It is clear that T-cell malfunction such as in advanced AIDS predisposes to severe disease. Resolution of infection with T cell reconstitution further illustrates the critical role of cellular immunity [85–87]. Furthermore, interferon gamma appears to be necessary for an effective immune response [88] and TNF- α , IL-4, IL-8, and IL-15 are also probably important [89–91]. Other situations of immune compromise that predispose to severe *Cryptosporidium* spp. infection include primary immune deficiencies, in particular x-linked immunodeficiency with hyper Ig M, hematologic malignancies, and transplants with chemotherapeutic immune suppression [92]. Deficient serum mannose-binding lectin (MBL) levels were associated with MBL2 gene promotor and structural region polymorphisms, specific MBL2 haplotypes, and increased symptomatic and recurrent *Cryptosporidium* infections in young children [93].

Evidence to support an active role for humoral immunity in protection from and clearance of infection is not conclusive. Indeed, although studies have shown that sero-conversion coincides with resolution of infection, subsequent infections are less severe after sero-conversion [61, 87, 94] and breast feeding may be associated with protection [95, 96], a specific causal link has not been proved. Moreover, other studies show that breast-feeding is either not protective [65] or results in greater incidence of infection [97]. A high level of specific antibodies in breast milk was actually found to be associated with a shorter time to first infection than low levels of specific antibodies [98].

Therapy and prevention

Therapy for *Cryptosporidium* spp. depends largely on immune status. The most important therapy is hydroelectrolytic resuscitation by mouth when practical or intra-venous as necessary. Restoration of immune status using anti-retroviral therapy is important in HIV/AIDS patients [99]. Protease inhibitors such as ritonavir, indinavir, and saquinavir have been found to have in-vitro and in vivo anti-cryptosporidial activity and can be specifically considered in these patients [100]. In cases of chemotherapeutic immune depression (e.g. hematologic malignancies and transplants), a decrease in the depth of immunosuppression may be helpful. When co-infection with a dysenteric pathogen is not present, antimotility agents permit absorption of water, electrolytes, and medications such as anti-retrovirals. Biliary involvement is treated with immune reconstitution and hepato-bilio-pancreatic procedures (e.g. cholecystectomy, ERCP with sphincterotomy and stent placement). Although a number of therapeutic agents have been evaluated for anti-cryptosporidial activity, only nitazoxanide has been approved by the US Food and Drug Administration (FDA). This drug has been shown to be beneficial in reducing duration and severity of symptoms in immune competent patients (adults and children) and mildly to moderately T cell deficient AIDS patients in 6 clinical trials involving 436 patients [99, 101]. The results have been less conclusive in profoundly immunodeficient patients, in particular HIV/AIDS patients with CD4 counts <50, and longer treatment courses have been thought to be warranted [99]. However, a recent double-blind, randomized, placebo controlled trial in

pediatric HIV patients in Zambia with 28 days of high dose nitazoxanide failed to show a benefit in clinical or parasitologic response [102]. Initial studies and experimental data looking at paramomycin in HIV patients showed some benefit [99]. However, the largest prospective, randomized, double-blind, placebo-controlled trial before the widespread introduction of highly active antiretroviral therapy found paromomycin to be no better than placebo [103]. The use of bovine dialyzable leukocyte extract [104] over 8 weeks or bovine hyperimmune colostrum over 10 days [105] versus placebo in HIV/AIDS patients with *Cryptosporidium* spp. showed no significant difference in stool frequency, consistency, volume, or parasitologic response. A 2007 meta-analysis concluded that the sum of evidence did not support a role for chemotherapy in the management of Cryptosporidiosis in immunocompromised patients [106].

Two studies looking at HIV patients receiving Mycobacterium avium complex (MAC) prophylaxis or treatment revealed that rifabutin, and possibly clarithromycin, were effective for cryptosporidiosis chemoprophylaxis [107, 108]. However, azithromycin used for MAC did not afford protection against *Cryptosporidium* spp. [108]. Although bovine hyperimmune anti-*Cryptosporidium* colostrum immunoglobulin decreases intensity of infection in vitro and in animal models [109, 110], its prophylactic use in a small number of *Cryptosporidium parvum* challenged healthy volunteers showed no difference in onset, intensity or duration of diarrhea versus nonfat milk placebo [111].

There is currently no vaccine to prevent *Cryptosporidium* spp. infection. The search for effective vaccine targets is ongoing.

Prevention of infection from water sources

The particularly hardy nature of *Cryptosporidium* spp. is such that conventional water treatment involving coagulation/flocculation, sedimentation, filtration, and disinfection may not be sufficient to clear contamination. Chlorination has been found to be insufficient to clear *Cryptosporidium* spp. [112]. Their small size (4–6µ) make oocysts more difficult to filter than larger protozoa such as *Giardia* and *Cyclospora*. The pliability and plasticity of oocysts is such that pore sizes less than 1 micron are necessary for effective filtration. Solar and UV-light disinfection are effective in reducing oocyst viability and infectivity [113, 114]. Solar photocatalytic disinfection (SPCDIS) using titanium oxide coated plastic inserts improves oocyst inactivation in water under overcast conditions [113]. When achievable, segregation of possible animal reservoirs from the water supply is desirable to reduce oocyst loads.

Constructed wetlands are a cost-effective way to treat wastewater as well as runoff from confined animal feeding operations (CAFO). These wetlands remove and biodegrade pathogens like *Cryptosporidium* spp. through sedimentation, filtration, attachment to plant roots and biofilms, predation, UV inactivation, and time-dependent die-off [115].

Improvements in water treatment and management are effective provided that there is no secondary contamination during transport, storage, and terminal use. In developing countries, hand washing, education, and point of use water treatment significantly improve

rates of diarrhea [116]. Water quality interventions can be effective without concomitant improved sanitation or more reliable water supplies [117].

In conclusion, *Cryptosporidium* spp. are significant pathogens worldwide; however, water treatment and good water management practices coupled with good nutrition and access to quality healthcare have mitigated its impact in the developed world. Effective specific treatment in immunocompromised individuals remains elusive. The full burden of *Cryptosporidium* spp. is still felt in the developing world.

Acknowledgments

SCA receives research support through the NIH grant 2 T32 AI007329-16.

References

1. Tyzzer EE. A sporozoan found in the peptic glands of the common mouse. *proc soc exp biol med*. 1907; 5:12–13.
2. Meisel JL, Perera DR, Meligro C, Rubin CE. Overwhelming watery diarrhea associated with a cryptosporidium in an immunosuppressed patient. *Gastroenterology*. 1976; 70:1156–1160. [PubMed: 773738]
3. Nime FA, Burek JD, Page DL, Holscher MA, Yardley JH. Acute enterocolitis in a human being infected with the protozoan *Cryptosporidium*. *Gastroenterology*. 1976; 70:592–598. [PubMed: 815126]
4. Guerrant RL. Cryptosporidiosis: an emerging, highly infectious threat. *Emerg Infect Dis*. 1997; 3:51–57. [PubMed: 9126444]
5. Ajjampur SS, Rajendran P, Ramani S, Banerjee I, Monica B, Sankaran P, Rosario V, Arumugam R, Sarkar R, Ward H, Kang G. Closing the diarrhoea diagnostic gap in Indian children by the application of molecular techniques. *J Med Microbiol*. 2008; 57:1364–8. [PubMed: 18927413]
6. Zu SX, Li JF, Barrett LJ, Fayer R, Shu SY, McAuliffe JF, Roche JK, Guerrant RL. Seroepidemiologic study of *Cryptosporidium* infection in children from rural communities of Anhui, China and Fortaleza, Brazil. *Am J Trop Med Hyg*. 1994; 51:1–10. [PubMed: 8059906]
7. Newman RD, Zu SX, Wuhib T, Lima AA, Guerrant RL, Sears CL. Household epidemiology of *Cryptosporidium parvum* infection in an urban community in northeast Brazil. *Ann Intern Med*. 1994; 120:500–505. [PubMed: 8311373]
8. Kozisek F, Craun GF, Cerovska L, Pumann P, Frost F, Muller T. Serological responses to *Cryptosporidium*-specific antigens in Czech populations with different water sources. *Epidemiol Infect*. 2008; 136:279–286. [PubMed: 17394676]
9. Egorov A, Frost F, Muller T, Naumova E, Tereschenko A, Ford T. Serological evidence of *Cryptosporidium* infections in a Russian city and evaluation of risk factors for infections. *Ann Epidemiol*. 2004; 14:129–136. [PubMed: 15018886]
10. Steinberg EB, Mendoza CE, Glass R, Arana B, Lopez MB, Mejia M, Gold BD, Priest JW, Bibb W, Monroe SS, Bern C, Bell BP, Hoekstra RM, Klein R, Mintz ED, Luby S. Prevalence of infection with waterborne pathogens: a seroepidemiologic study in children 6–36 months old in San Juan Sacatepequez, Guatemala. *Am J Trop Med Hyg*. 2004; 70:83–88. [PubMed: 14971703]
11. Frost FJ, Muller T, Craun GF, Lockwood WB, Calderon RL. Serological evidence of endemic waterborne cryptosporidium infections. *Ann Epidemiol*. 2002; 12:222–227. [PubMed: 11988409]
12. Frost FJ, Fea E, Gilli G, Biorci F, Muller TM, Craun GF, Calderon RL. Serological evidence of *Cryptosporidium* infections in southern Europe. *Eur J Epidemiol*. 2000; 16:385–390. [PubMed: 10959948]
13. Isaac-Renton J, Blatherwick J, Bowie WR, Fyfe M, Khan M, Li A, King A, McLean M, Medd L, Moorehead W, Ong CS, Robertson W. Epidemic and endemic seroprevalence of antibodies to *Cryptosporidium* and *Giardia* in residents of three communities with different drinking water supplies. *Am J Trop Med Hyg*. 1999; 60:578–583. [PubMed: 10348231]

14. Communitywide cryptosporidiosis outbreak--Utah 2007. *MMWR Morb Mortal Wkly Rep.* 2008; 57:989–93. [PubMed: 18784640]
15. Jokipii L, Jokipii AM. Timing of symptoms and oocyst excretion in human cryptosporidiosis. *N Engl J Med.* 1986; 315:1643–1647. [PubMed: 2431315]
16. van Gool T, Weijts R, Lommerse E, Mank TG. Triple Faeces Test: an effective tool for detection of intestinal parasites in routine clinical practice. *Eur J Clin Microbiol Infect Dis.* 2003; 22:284–290. [PubMed: 12736794]
17. Centers for Disease Control and Prevention (CDC) . False-positive laboratory tests for *Cryptosporidium* involving an enzyme-linked immunosorbent assay--United States, November 1997–March 1998. *MMWR Morb Mortal Wkly Rep.* 1999; 48:4–8. [PubMed: 9933121]
18. Robinson G, Watkins J, Chalmers RM. Evaluation of a modified semi-automated immunomagnetic separation technique for the detection of *Cryptosporidium* oocysts in human faeces. *J Microbiol Methods.* 2008; 75:139–141. [PubMed: 18571261]
19. Rochelle PA, Ferguson DM, Johnson AM, De Leon R. Quantitation of *Cryptosporidium parvum* infection in cell culture using a colorimetric in situ hybridization assay. *J Eukaryot Microbiol.* 2001; 48:565–574. [PubMed: 11596921]
20. Xiao L. Molecular epidemiology of cryptosporidiosis: An update. *Exp Parasitol.* 2009
21. [Accessed December 17, 2009] Method 1623: *Cryptosporidium* and *Giardia* in Water by Filtration/IMS/FA. <http://www.epa.gov/nerlcwww/1623de05.pdf>
22. Jenkins MB, Anguish LJ, Bowman DD, Walker MJ, Ghiorse WC. Assessment of a dye permeability assay for determination of inactivation rates of *Cryptosporidium parvum* oocysts. *Appl Environ Microbiol.* 1997; 63:3844–3850. [PubMed: 9327547]
23. Bukhari Z, Marshall MM, Korich DG, Fricker CR, Smith HV, Rosen J, Clancy JL. Comparison of *Cryptosporidium parvum* viability and infectivity assays following ozone treatment of oocysts. *Appl Environ Microbiol.* 2000; 66:2972–2980. [PubMed: 10877794]
24. Lemos V, Graczyk TK, Alves M, Lobo ML, Sousa MC, Antunes F, Matos O. Identification and determination of the viability of *Giardia lamblia* cysts and *Cryptosporidium parvum* and *Cryptosporidium hominis* oocysts in human fecal and water supply samples by fluorescent in situ hybridization (FISH) and monoclonal antibodies. *Parasitol Res.* 2005; 98:48–53. [PubMed: 16261356]
25. Alagappan A, Tujula NA, Power M, Ferguson CM, Bergquist PL, Ferrari BC. Development of fluorescent in situ hybridization for *Cryptosporidium* detection reveals zoonotic and anthroponotic transmission of sporadic cryptosporidiosis in Sydney. *J Microbiol Methods.* 2008; 75:535–9. [PubMed: 18789979]
26. Alagappan A, Bergquist PL, Ferrari BC. Development of a two-color fluorescence in situ hybridization technique for species-level identification of human-infectious *Cryptosporidium* spp. *Appl Environ Microbiol.* 2009; 75:5996–5998. [PubMed: 19633112]
27. Jenkins M, Trout JM, Higgins J, Dorsch M, Veal D, Fayer R. Comparison of tests for viable and infectious *Cryptosporidium parvum* oocysts. *Parasitol Res.* 2003; 89:1–5. [PubMed: 12474036]
28. Rochelle PA, Marshall MM, Mead JR, Johnson AM, Korich DG, Rosen JS, De Leon R. Comparison of in vitro cell culture and a mouse assay for measuring infectivity of *Cryptosporidium parvum*. *Appl Environ Microbiol.* 2002; 68:3809–3817. [PubMed: 12147476]
29. Tzipori S, Ward H. Cryptosporidiosis: biology, pathogenesis and disease. *Microbes Infect.* 2002; 4:1047–1058. [PubMed: 12191655]
30. Chen XM, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. *N Engl J Med.* 2002; 346:1723–1731. [PubMed: 12037153]
31. Caccio SM, Thompson RC, McLauchlin J, Smith HV. Unravelling *Cryptosporidium* and *Giardia* epidemiology. *Trends Parasitol.* 2005; 21:430–437. [PubMed: 16046184]
32. Leav BA, Mackay M, Ward HD. *Cryptosporidium* species: new insights and old challenges. *Clin Infect Dis.* 2003; 36:903–908. [PubMed: 12652391]
33. Martinez-Giron R, Esteban JG, Ribas A, Doganci L. Protozoa in respiratory pathology: a review. *Eur Respir J.* 2008; 32:1354–70. [PubMed: 18978136]
34. Chalmers RM, Davies AP. Minireview: Clinical cryptosporidiosis. *Exp Parasitol.* 2009

35. Graczyk TK, Fayer R, Knight R, Mhangami-Ruwende B, Trout JM, Da Silva AJ, Pieniazek NJ. Mechanical transport and transmission of *Cryptosporidium parvum* oocysts by wild filth flies. *Am J Trop Med Hyg.* 2000; 63:178–183. [PubMed: 11388511]
36. Miller WA, Lewis DJ, Pereira MD, Lennox M, Conrad PA, Tate KW, Atwill ER. Farm factors associated with reducing *Cryptosporidium* loading in storm runoff from dairies. *J Environ Qual.* 2008; 37:1875–82. [PubMed: 18689749]
37. Mahdi NK, Ali NH. Cryptosporidiosis among animal handlers and their livestock in Basrah, Iraq. *East Afr Med J.* 2002; 79:550–553. [PubMed: 12635763]
38. Robertson LJ. *Giardia* and *Cryptosporidium* infections in sheep and goats: a review of the potential for transmission to humans via environmental contamination. *Epidemiol Infect.* 2009; 137:913–21. [PubMed: 19272199]
39. Smerdon WJ, Nichols T, Chalmers RM, Heine H, Reacher MH. Foot and mouth disease in livestock and reduced cryptosporidiosis in humans, England and Wales. *Emerg Infect Dis.* 2003; 9:22–28. [PubMed: 12533277]
40. Huetink RE, van der Giessen JW, Noordhuizen JP, Ploeger HW. Epidemiology of *Cryptosporidium* spp. and *Giardia duodenalis* on a dairy farm. *Vet Parasitol.* 2001; 102:53–67. [PubMed: 11705652]
41. King BJ, Keegan AR, Monis PT, Saint CP. Environmental temperature controls *Cryptosporidium* oocyst metabolic rate and associated retention of infectivity. *Appl Environ Microbiol.* 2005; 71:3848–3857. [PubMed: 16000797]
42. Deng MQ, Cliver DO. *Cryptosporidium parvum* studies with dairy products. *Int J Food Microbiol.* 1999; 46:113–121. [PubMed: 10728612]
43. McGuigan KG, Mendez-Hermida F, Castro-Hermida JA, Ares-Mazas E, Kehoe SC, Boyle M, Sichel C, Fernandez-Ibanez P, Meyer BP, Ramalingham S, Meyer EA. Batch solar disinfection inactivates oocysts of *Cryptosporidium parvum* and cysts of *Giardia muris* in drinking water. *J Appl Microbiol.* 2006; 101:453–463. [PubMed: 16882154]
44. King BJ, Hoefel D, Daminato DP, Fanok S, Monis PT. Solar UV reduces *Cryptosporidium parvum* oocyst infectivity in environmental waters. *J Appl Microbiol.* 2008; 104:1311–23. [PubMed: 18248370]
45. Connelly SJ, Wolyniak EA, Williamson CE, Jellison KL. Artificial UV-B and solar radiation reduce in vitro infectivity of the human pathogen *Cryptosporidium parvum*. *Environ Sci Technol.* 2007; 41:7101–6. [PubMed: 17993154]
46. Linden KG, Shin G, Sobsey MD. Comparative effectiveness of UV wavelengths for the inactivation of *Cryptosporidium parvum* oocysts in water. *Water Sci Technol.* 2001; 43:171–174. [PubMed: 11464748]
47. Lorenzo-Lorenzo MJ, Ares-Mazas ME, Villacorta-Martinez de Maturana I, Duran-Oreiro D. Effect of ultraviolet disinfection of drinking water on the viability of *Cryptosporidium parvum* oocysts. *J Parasitol.* 1993; 79:67–70. [PubMed: 8437060]
48. Rochelle PA, Fallar D, Marshall MM, Montelone BA, Upton SJ, Woods K. Irreversible UV inactivation of *Cryptosporidium* spp. despite the presence of UV repair genes. *J Eukaryot Microbiol.* 2004; 51:553–562. [PubMed: 15537090]
49. Johnson AM, Linden K, Ciociola KM, De Leon R, Widmer G, Rochelle PA. UV inactivation of *Cryptosporidium hominis* as measured in cell culture. *Appl Environ Microbiol.* 2005; 71:2800–2802. [PubMed: 15870378]
50. Atwill ER, Tate KW, Pereira MD, Bartolome J, Nader G. Efficacy of natural grassland buffers for removal of *Cryptosporidium parvum* in rangeland runoff. *J Food Prot.* 2006; 69:177–184. [PubMed: 16416916]
51. Bodley-Tickell AT, Kitchen SE, Sturdee AP. Occurrence of *Cryptosporidium* in agricultural surface waters during an annual farming cycle in lowland UK. *Water Res.* 2002; 36:1880–1886. [PubMed: 12044087]
52. Naumova EN, Jagai JS, Matyas B, AD, MacNeill IB, Griffiths JK. Seasonality in six enterically transmitted diseases and ambient temperature. *Epidemiol Infect.* 2007; 135:281–92. [PubMed: 17291363]

53. Jagai JS, Castronovo DA, Monchak J, Naumova EN. Seasonality of cryptosporidiosis: A meta-analysis approach. *Environ Res.* 2009; 109:465–78. [PubMed: 19328462]
54. Muchiri JM, Ascolillo L, Mugambi M, Mutwiri T, Ward HD, Naumova EN, Egorov AI, Cohen S, Else JG, Griffiths JK. Seasonality of *Cryptosporidium* oocyst detection in surface waters of Meru, Kenya as determined by two isolation methods followed by PCR. *J Water Health.* 2009; 7:67–75. [PubMed: 18957776]
55. Okhuysen PC, Rich SM, Chappell CL, Grimes KA, Widmer G, Feng X, Tzipori S. Infectivity of a *Cryptosporidium parvum* isolate of cervine origin for healthy adults and interferon-gamma knockout mice. *J Infect Dis.* 2002; 185:1320–1325. [PubMed: 12001050]
56. Messner MJ, Chappell CL, Okhuysen PC. Risk assessment for *Cryptosporidium*: a hierarchical Bayesian analysis of human dose response data. *Water Res.* 2001; 35:3934–3940. [PubMed: 12230176]
57. Chappell CL, Okhuysen PC, Langer-Curry R, Widmer G, Akiyoshi DE, Tanriverdi S, Tzipori S. *Cryptosporidium hominis*: experimental challenge of healthy adults. *Am J Trop Med Hyg.* 2006; 75:851–857. [PubMed: 17123976]
58. DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB, Jakubowski W. The infectivity of *Cryptosporidium parvum* in healthy volunteers. *N Engl J Med.* 1995; 332:855–859. [PubMed: 7870140]
59. Okhuysen PC, Chappell CL, Crabb JH, Sterling CR, DuPont HL. Virulence of three distinct *Cryptosporidium parvum* isolates for healthy adults. *J Infect Dis.* 1999; 180:1275–1281. [PubMed: 10479158]
60. Okhuysen PC, Chappell CL, Sterling CR, Jakubowski W, DuPont HL. Susceptibility and serologic response of healthy adults to reinfection with *Cryptosporidium parvum*. *Infect Immun.* 1998; 66:441–443. [PubMed: 9453592]
61. Chappell CL, Okhuysen PC, Sterling CR, Wang C, Jakubowski W, Dupont HL. Infectivity of *Cryptosporidium parvum* in healthy adults with pre-existing anti-*C. parvum* serum immunoglobulin G. *Am J Trop Med Hyg.* 1999; 60:157–164. [PubMed: 9988341]
62. Mac Kenzie WR, Hoxie NJ, Proctor ME, Gradus MS, Blair KA, Peterson DE, Kazmierczak JJ, Addiss DG, Fox KR, Rose JB. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. *N Engl J Med.* 1994; 331:161–167. [PubMed: 7818640]
63. Pawlowski SW, Warren CA, Guerrant R. Diagnosis and treatment of acute or persistent diarrhea. *Gastroenterology.* 2009; 136:1874–1886. [PubMed: 19457416]
64. Dillingham RA, Lima AA, Guerrant RL. Cryptosporidiosis: epidemiology and impact. *Microbes Infect.* 2002; 4:1059–1066. [PubMed: 12191656]
65. Khan WA, Rogers KA, Karim MM, Ahmed S, Hibberd PL, Calderwood SB, Ryan ET, Ward HD. Cryptosporidiosis among Bangladeshi children with diarrhea: a prospective, matched, case-control study of clinical features, epidemiology and systemic antibody responses. *Am J Trop Med Hyg.* 2004; 71:412–419. [PubMed: 15516636]
66. Egger M, Mausezahl D, Odermatt P, Marti HP, Tanner M. Symptoms and transmission of intestinal cryptosporidiosis. *Arch Dis Child.* 1990; 65:445–447. [PubMed: 2346340]
67. Hunter PR, Hughes S, Woodhouse S, Raj N, Syed Q, Chalmers RM, Verlander NQ, Goodacre J. Health sequelae of human cryptosporidiosis in immunocompetent patients. *Clin Infect Dis.* 2004; 39:504–510. [PubMed: 15356813]
68. Vakil NB, Schwartz SM, Buggy BP, Brummitt CF, Kherallah M, Letzer DM, Gilson IH, Jones PG. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. *N Engl J Med.* 1996; 334:19–23. [PubMed: 7494565]
69. Lopez-Velez R, Tarazona R, Garcia Camacho A, Gomez-Mampaso E, Guerrero A, Moreira V, Villanueva R. Intestinal and extraintestinal cryptosporidiosis in AIDS patients. *Eur J Clin Microbiol Infect Dis.* 1995; 14:677–681. [PubMed: 8565984]
70. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. *J Infect.* 2001; 42:134–139. [PubMed: 11531320]

71. Zardi EM, Picardi A, Afeltra A. Treatment of cryptosporidiosis in immunocompromised hosts. *Chemotherapy*. 2005; 51:193–196. [PubMed: 16006765]
72. Guerrant DI, Moore SR, Lima AA, Patrick PD, Schorling JB, Guerrant RL. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil. *Am J Trop Med Hyg*. 1999; 61:707–713. [PubMed: 10586898]
73. Checkley W, Buckley G, Gilman RH, Assis AM, Guerrant RL, Morris SS, Molbak K, Valentiner-Branth P, Lanata CF, Black RE. Childhood Malnutrition and Infection Network . Multi-country analysis of the effects of diarrhoea on childhood stunting. *Int J Epidemiol*. 2008; 37:816–830. [PubMed: 18567626]
74. Molbak K, Andersen M, Aaby P, Hojlyng N, Jakobsen M, Sodemann M, da Silva AP. Cryptosporidium infection in infancy as a cause of malnutrition: a community study from Guinea-Bissau, west Africa. *Am J Clin Nutr*. 1997; 65:149–152. [PubMed: 8988927]
75. Kirkpatrick BD, Noel F, Rouzier PD, Powell JL, Pape JW, Bois G, Alston WK, Larsson CJ, Tenney K, Ventrone C, Powden C, Sreenivasan M, Sears CL. Childhood cryptosporidiosis is associated with a persistent systemic inflammatory response. *Clin Infect Dis*. 2006; 43:604–608. [PubMed: 16886154]
76. Molbak K, Hojlyng N, Gottschau A, Sa JC, Ingholt L, da Silva AP, Aaby P. Cryptosporidiosis in infancy and childhood mortality in Guinea Bissau, west Africa. *BMJ*. 1993; 307:417–420. [PubMed: 8374453]
77. Yang W, Chen P, Villegas EN, Landy RB, Kanetsky C, Cama V, Dearen T, Schultz CL, Orndorff KG, Prelewicz GJ, Brown MH, Young KR, Xiao L. Cryptosporidium source tracking in the Potomac River watershed. *Appl Environ Microbiol*. 2008; 74:6495–504. [PubMed: 18776033]
78. Morgan-Ryan UM, Fall A, Ward LA, Hijjawi N, Sulaiman I, Fayer R, Thompson RC, Olson M, Lal A, Xiao L. Cryptosporidium hominis n. sp. (Apicomplexa: Cryptosporidiidae) from Homo sapiens. *J Eukaryot Microbiol*. 2002; 49:433–440. [PubMed: 12503676]
79. Baishanbo A, Gargala G, Delaunay A, Francois A, Ballet JJ, Favenne L. Infectivity of Cryptosporidium hominis and Cryptosporidium parvum genotype 2 isolates in immunosuppressed Mongolian gerbils. *Infect Immun*. 2005; 73:5252–5255. [PubMed: 16041051]
80. Bushen OY, Kohli A, Pinkerton RC, Dupnik K, Newman RD, Sears CL, Fayer R, Lima AA, Guerrant RL. Heavy cryptosporidial infections in children in northeast Brazil: comparison of Cryptosporidium hominis and Cryptosporidium parvum. *Trans R Soc Trop Med Hyg*. 2007; 101:378–384. [PubMed: 16934303]
81. Ajajampur SS, Gladstone BP, Selvapandian D, Muliyl JP, Ward H, Kang G. Molecular and spatial epidemiology of cryptosporidiosis in children in a semiurban community in South India. *J Clin Microbiol*. 2007; 45:915–920. [PubMed: 17251402]
82. Cama VA, Bern C, Roberts J, Cabrera L, Sterling CR, Ortega Y, Gilman RH, Xiao L. Cryptosporidium species and subtypes and clinical manifestations in children, Peru. *Emerg Infect Dis*. 2008; 14:1567–74. [PubMed: 18826821]
83. Rao Ajajampur SS, Asirvatham JR, Muthusamy D, Gladstone BP, Abraham OC, Mathai D, Ward H, Wanke C, Kang G. Clinical features & risk factors associated with cryptosporidiosis in HIV infected adults in India. *Indian J Med Res*. 2007; 126:553–7. [PubMed: 18219083]
84. Cama VA, Ross JM, Crawford S, Kawai V, Chavez-Valdez R, Vargas D, Vivar A, Ticona E, Navincopa M, Williamson J, Ortega Y, Gilman RH, Bern C, Xiao L. Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons. *J Infect Dis*. 2007; 196:684–91. [PubMed: 17674309]
85. Schmidt W, Wahnschaffe U, Schafer M, Zippel T, Arvand M, Meyerhans A, Riecken EO, Ullrich R. Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy. *Gastroenterology*. 2001; 120:984–987. [PubMed: 11231952]
86. Pozio E, Rezza G, Boschini A, Pezzotti P, Tamburrini A, Rossi P, Di Fine M, Smacchia C, Schiesari A, Gattei E, Zucconi R, Ballarini P. Clinical cryptosporidiosis and human immunodeficiency virus (HIV)-induced immunosuppression: findings from a longitudinal study of HIV-positive and HIV-negative former injection drug users. *J Infect Dis*. 1997; 176:969–975. [PubMed: 9333155]

87. Riggs MW. Recent advances in cryptosporidiosis: the immune response. *Microbes Infect.* 2002; 4:1067–1080. [PubMed: 12191657]
88. Theodos CM. Innate and cell-mediated immune responses to *Cryptosporidium parvum*. *Adv Parasitol.* 1998; 40:87–119. [PubMed: 9554071]
89. Theodos CM, Sullivan KL, Griffiths JK, Tzipori S. Profiles of healing and nonhealing *Cryptosporidium parvum* infection in C57BL/6 mice with functional B and T lymphocytes: the extent of gamma interferon modulation determines the outcome of infection. *Infect Immun.* 1997; 65:4761–4769. [PubMed: 9353062]
90. Robinson P, Okhuysen PC, Chappell CL, Lewis DE, Shahab I, Lahoti S, White AC Jr. Expression of IL-15 and IL-4 in IFN-gamma-independent control of experimental human *Cryptosporidium parvum* infection. *Cytokine.* 2001; 15:39–46. [PubMed: 11509007]
91. Lean IS, McDonald SA, Bajaj-Elliott M, Pollok RC, Farthing MJ, McDonald V. Interleukin-4 and transforming growth factor beta have opposing regulatory effects on gamma interferon-mediated inhibition of *Cryptosporidium parvum* reproduction. *Infect Immun.* 2003; 71:4580–4585. [PubMed: 12874337]
92. Hunter PR, Nichols G. Epidemiology and clinical features of *Cryptosporidium* infection in immunocompromised patients. *Clin Microbiol Rev.* 2002; 15:145–154. [PubMed: 11781272]
93. Carmolli M, Duggal P, Haque R, Lindow J, Mondal D, Petri WA Jr, Mourningstar P, Larsson CJ, Sreenivasan M, Khan S, Kirkpatrick BD. Deficient serum mannose-binding lectin levels and MBL2 polymorphisms increase the risk of single and recurrent *Cryptosporidium* infections in young children. *J Infect Dis.* 2009; 200:1540–1547. [PubMed: 19827946]
94. Moss DM, Chappell CL, Okhuysen PC, DuPont HL, Arrowood MJ, Hightower AW, Lammie PJ. The antibody response to 27-, 17-, and 15-kDa *Cryptosporidium* antigens following experimental infection in humans. *J Infect Dis.* 1998; 178:827–833. [PubMed: 9728553]
95. Bhattacharya MK, Teka T, Faruque AS, Fuchs GJ. *Cryptosporidium* infection in children in urban Bangladesh. *J Trop Pediatr.* 1997; 43:282–286. [PubMed: 9364126]
96. Molbak K, Aaby P, Hojlyng N, da Silva AP. Risk factors for *Cryptosporidium* diarrhea in early childhood: a case-control study from Guinea-Bissau, West Africa. *Am J Epidemiol.* 1994; 139:734–740. [PubMed: 8166134]
97. Nchito M, Kelly P, Sianongo S, Luo NP, Feldman R, Farthing M, Baboo KS. Cryptosporidiosis in urban Zambian children: an analysis of risk factors. *Am J Trop Med Hyg.* 1998; 59:435–437. [PubMed: 9749640]
98. Sterling CR, Gilman RH, Sinclair NA, Cama V, Castillo R, Diaz F. The role of breast milk in protecting urban Peruvian children against cryptosporidiosis. *J Protozool.* 1991; 38:23S–25S. [PubMed: 1818182]
99. Rossignol JF. *Cryptosporidium* and *Giardia*: Treatment Options and Prospects for New Drugs. *Exp Parasitol.* 2009
100. Hommer V, Eichholz J, Petry F. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of *Cryptosporidium parvum*. *J Antimicrob Chemother.* 2003; 52:359–364. [PubMed: 12888587]
101. Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. *Lancet.* 2002; 360:1375–1380. [PubMed: 12423984]
102. Amadi B, Mwiya M, Sianongo S, Payne L, Watuka A, Katubulushi M, Kelly P. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. *BMC Infect Dis.* 2009; 9:195. [PubMed: 19954529]
103. Hewitt RG, Yiannoutsos CT, Higgs ES, Carey JT, Geiseler PJ, Soave R, Rosenberg R, Vazquez GJ, Wheat LJ, Fass RJ, Antoninievic Z, Walawander AL, Flanigan TP, Bender JF. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. *Clin Infect Dis.* 2000; 31:1084–1092. [PubMed: 11049793]

104. McMeeking A, Borkowsky W, Klesius PH, Bonk S, Holzman RS, Lawrence HS. A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. *J Infect Dis.* 1990; 161:108–112. [PubMed: 2404072]
105. Nord J, Ma P, DiJohn D, Tzipori S, Tacket CO. Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. *AIDS.* 1990; 4:581–584. [PubMed: 2201320]
106. Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Prevention and treatment of cryptosporidiosis in immunocompromised patients. *Cochrane Database Syst Rev.* 2007; (1):CD004932. [PubMed: 17253532]
107. Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK. AIDS Clinical Trials Group New Works Concept Sheet Team 064. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. *AIDS.* 2000; 14:2889–2893. [PubMed: 11153670]
108. Holmberg SD, Moorman AC, Von Bargen JC, Palella FJ, Loveless MO, Ward DJ, Navin TR. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. *JAMA.* 1998; 279:384–386. [PubMed: 9459473]
109. Jenkins MC, O'Brien C, Trout J, Guidry A, Fayer R. Hyperimmune bovine colostrum specific for recombinant *Cryptosporidium parvum* antigen confers partial protection against cryptosporidiosis in immunosuppressed adult mice. *Vaccine.* 1999; 17:2453–2460. [PubMed: 10392628]
110. Doyle PS, Crabb J, Petersen C. Anti-*Cryptosporidium parvum* antibodies inhibit infectivity in vitro and in vivo. *Infect Immun.* 1993; 61:4079–4084. [PubMed: 8406795]
111. Okhuysen PC, Chappell CL, Crabb J, Valdez LM, Douglass ET, DuPont HL. Prophylactic effect of bovine anti-*Cryptosporidium* hyperimmune colostrum immunoglobulin in healthy volunteers challenged with *Cryptosporidium parvum*. *Clin Infect Dis.* 1998; 26:1324–1329. [PubMed: 9636857]
112. Betancourt WQ, Rose JB. Drinking water treatment processes for removal of *Cryptosporidium* and *Giardia*. *Vet Parasitol.* 2004; 126:219–234. [PubMed: 15567586]
113. Mendez-Hermida F, Ares-Mazas E, McGuigan KG, Boyle M, Sichel C, Fernandez-Ibanez P. Disinfection of drinking water contaminated with *Cryptosporidium parvum* oocysts under natural sunlight and using the photocatalyst TiO₂. *J Photochem Photobiol B.* 2007; 88:105–111. [PubMed: 17624798]
114. King BJ, Monis PT. Critical processes affecting *Cryptosporidium* oocyst survival in the environment. *Parasitology.* 2007; 134:309–23. [PubMed: 17096874]
115. Graczyk TK, Lucy FE, Tamang L, Mashinski Y, Broaders MA, Connolly M, Cheng HW. Propagation of human enteropathogens in constructed horizontal wetlands used for tertiary wastewater treatment. *Appl Environ Microbiol.* 2009; 75:4531–8. [PubMed: 19411413]
116. Fewtrell L, Kaufmann RB, Kay D, Enanoria W, Haller L, Colford JM Jr. Water, sanitation, and hygiene interventions to reduce diarrhoea in less developed countries: a systematic review and meta-analysis. *Lancet Infect Dis.* 2005; 5:42–52. [PubMed: 15620560]
117. Clasen T, Schmidt WP, Rabie T, Roberts I, Cairncross S. Interventions to improve water quality for preventing diarrhoea: systematic review and meta-analysis. *BMJ.* 2007; 334:782. [PubMed: 17353208]